GRI Bio (NASDAQ:GRI) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen cut shares of GRI Bio (NASDAQ:GRI) to a strong sell rating in a research report report published on Saturday.

A number of other research analysts also recently issued reports on GRI. Ascendiant Capital Markets lifted their price target on GRI Bio from $980.00 to $1,008.00 and gave the company a “buy” rating in a report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GRI Bio in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $644.00.

GRI Bio Stock Performance

NASDAQ GRI opened at $2.86 on Friday. GRI Bio has a one year low of $2.71 and a one year high of $314.16. The company has a market capitalization of $1.54 million, a price-to-earnings ratio of -0.34 and a beta of -1.40. The company’s 50-day simple moving average is $18.27 and its two-hundred day simple moving average is $38.06.

GRI Bio (NASDAQ:GRI) last released its quarterly earnings data on Friday, November 14th. The company reported ($35.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($31.08) by ($4.76). Equities analysts expect that GRI Bio will post -3.04 earnings per share for the current fiscal year.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.